Abstracts tagged "Biomarkers"

Abstract Number: 1345 • 2013 ACR/ARHP Annual Meeting
Retinal Vascular Calibre – a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis
John HY Moi^1,2, Lauren AB Hodgson^3,4,5, Ian P Wicks^1,6,7, Tien Yin Wong^3,4,5,8 and Sharon Van Doornum^1,3,9, ¹Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ²Department of Medicine, The University of Melbourne, Melbourne, Australia, ³The University of Melbourne, Melbourne, Australia, ⁴Royal Victorian Eye and Ear Hospital, Melbourne, Australia, ⁵Centre for Eye Research Australia, Melbourne, Australia, ⁶Department of Medical Biology, University of Melbourne, Parkville, Australia, ⁷Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia, ⁸Singapore Eye Research Institute, Singapore, Singapore, ⁹Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Retinal vascular calibre measurement is a non-invasive tool for assessing systemic and vascular health. Widened retinal venular calibre (RVC) is associated with systemic inflammation,…
Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
M. C. Genovese¹, T. Kawabata², K. Soma², S. Menon², J.D. Clark³, J. Hodge⁴, L. Takiya⁴, R. Riese² and S. Krishnaswami⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…
Abstract Number: 149 • 2013 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Teisuke Uchida¹, Kohei Nagai², Toshiyuki Sato³, Nobuko Iizuka³, Mitsumi Arito³, Yukiko Takakuwa⁴, Hiromasa Nakano⁴, Seido Ooka⁴, Manae Kurokawa³, Naoya Suematsu³, Kazuki Okamoto³, Shoichi Ozaki⁵ and Tomohiro Kato³, ¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, kawasaki, Japan, ²Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kinki University, Wakayama, Japan, ³Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ⁴Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which neutrophils are thought to be involved in their…
Abstract Number: 2412 • 2013 ACR/ARHP Annual Meeting
Anti-CCP Antibodies and Increased Cartilage Turnover In Patients Developing Rheumatoid Arthritis
Carl Turesson¹, Christina Book², Ulf Bergström², Lennart Truedsson³, Lennart Jacobsson² and Tore Saxne⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ⁴Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Autoantibodies may be detected years before the onset of rheumatoid arthritis (RA). We have previously shown that levels of Cartilage oligomeric matrix protein (COMP),…
Abstract Number: 1869 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients
Hitoshi Uga¹, Takahiro Okazawa¹, Yoshiaki Miyamoto¹, Takehiro Hasegawa¹, Jun Saegusa², Goh Tsuji³, Sho Sendo⁴, Akio Morinobu⁵, Shunichi Kumagai^6,7 and Hirokazu Kurata¹, ¹Sysmex Corporation, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ⁷Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The diagnosis of anti-CCP antibody (ACPA) negative rheumatoid arthritis (RA) are known to be difficult and delayed as compared with ACPA-positive RA. This study…
Abstract Number: 1347 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study
I.M. Markusse¹, L. Dirven¹, M. van den Broek¹, K.H. Han², M.F. van Lieshout³, N. Riyazi⁴, R.J. Bolce⁵, E.H. Sasso⁵, P.J.S.M. Kerstens⁶, W.F. Lems⁷, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Spaarne Hospital, Hoofddorp, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: To determine whether a multi-biomarker disease activity (MBDA) score could predict radiographic damage progression in patients with rheumatoid arthritis (RA). Methods: The BeSt study…
Abstract Number: 458 • 2013 ACR/ARHP Annual Meeting
High Levels Of Natural Killer CELLS ARE Associated With Response To Tocilizumab In Patients With Severe Rheumatoid Arthritis
Claire I. Daien^1,2, Sarah Gailhac³, Rachel Audo¹, Thibault Mura⁴, Michael Hahne¹, Bernard Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Inhibition of interleukin 6 (IL-6) receptor with tocilizumab (TCZ) is effective for rheumatoid arthritis (RA). However, the effect of TCZ on lymphocytes remains poorly…
Abstract Number: 2616 • 2012 ACR/ARHP Annual Meeting
The Transition From Psoriasis (Ps) to Psoriatic Arthritis (PsA) Is Associated with Elevated Circulating Osteoclast Precursors (OCP) and Increased Expression of DC-STAMP
Ya-Hui Chiu¹, Edward M. Schwarz², Dafna D. Gladman³, Sharon Moorehead⁴, Michelle Smith⁴, Rick Barrett⁴ and Christopher T. Ritchlin⁴, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Approximately 20% of psoriasis (Ps) patients (pts) develop psoriatic arthritis (PsA). Early diagnosis and therapy of PsA can limit bone and joint damage; however,…
Abstract Number: 2167 • 2012 ACR/ARHP Annual Meeting
Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab
Anne C. Bay-Jensen¹, Inger Byrjalsen², Claus Christiansen³ and Morten Asser Karsdal⁴, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³CCBR, Ballerup, Denmark, ⁴Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: RA is characterized by synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease early…
Abstract Number: 1263 • 2012 ACR/ARHP Annual Meeting
Carotid Arterial Wall Inflammation Is Associated with a Specific Profile of Inflammatory Biomarkers and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients
Caroline Grönwall¹, Gregg J. Silverman¹, Zahi Fayad², Venkatesh Mani², Victoria Furer³, Michael Farkouh², Manish Jain¹, Cheongeun Oh⁴, John Todd⁵, Mukundan Attur⁶, Steven B. Abramson⁷ and Jeffrey D. Greenberg⁸, ¹Rheumatology, NYU School of Medicine, New York, NY, ²Mount Sinai Hospital, New York, NY, ³Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Biostatistics, NYU School of Medicine, New York, NY, ⁵Singulex, Alameda, California, Alameda, CA, ⁶Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁷Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ⁸New York Hospital for Joint Disease, New York, NY
Background/Purpose: Patients with RA are at increased risk of cardiovascular (CV) comorbidity and premature mortality. While generally attributed to accelerated atherosclerosis, the pathogenesis remains poorly understood.…
Abstract Number: 755 • 2012 ACR/ARHP Annual Meeting
Sifalimumab, an Anti-IFN-Alpha Monoclonal Antibody Shows Target Suppression of a Type I IFN Signature in Blood and Muscle of Dermatomyositis and Polymyositis Patients
Brandon W. Higgs¹, Wei Zhu², Chris Morehouse¹, Wendy White³, Philip Brohawn¹, Charles Le⁴, Anthony A Amato⁵, David Fiorentino⁶, Steven A. Greenberg⁵, Laura Richman¹, Warren Greth⁴, Bahija Jallal¹ and Yihong Yao³, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Science, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD, ⁴Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-alpha monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by…
Abstract Number: 333 • 2012 ACR/ARHP Annual Meeting
Pressure and Blood Flow Measurements in Efferent Lymphatics As Biomarkers of Arthritic Flare
Echoe M. Bouta¹, Ronald Wood², Christopher T. Ritchlin³, Lianping Xing⁴ and Edward M. Schwarz⁵, ¹University of Rochester, Rochester, NY, ²Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with episodic flares in affected joints. These flares are associated with decreased lymphatic drainage. In TNF-Tg mice,…
Abstract Number: 2593 • 2012 ACR/ARHP Annual Meeting
Predictive Markers of Therapeutical Outcome and Their Role in the Ethiopathology of Juvenile Idiopathic Arthritis
Maura Rossetti¹, Roberto Spreafico¹, Hong Zhang¹, Maryam Moshref¹, Nora G. Singer², D. J. Lovell³, Carol A. Wallace⁴ and Salvatore Albani⁵, ¹Translational Immunology, Sanford-Burnham Medical Research Institute, La Jolla, CA, ²Rheumatology, MetroHealth Medical Center, Cleveland, OH, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁵Translational Research Program, Infectious and Inflammatory Diseases, Sanford-Burnham Medical Research Institute, La Jolla, CA
Background/Purpose: Currently, juvenile idiopathic arthritis (JIA) is treated with methotrexate (MTX) as a first-line agent. If children fail to respond, a biologic (e.g. anti-TNF) is…
Abstract Number: 2121 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Yoshiya Tanaka¹, Kentaro Hanami², Hisashi Tasaka¹, Shunsuke Fukuyo¹, Douglas J. Haney³, Nadine Defranoux³, Rebecca Bolce³, Guy Cavet³, David Chernoff³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Shintaro Hirata¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with…
Abstract Number: 1203 • 2012 ACR/ARHP Annual Meeting
High Expression of Genes in the Toll-Like Receptor and Interferon Pathways Are Associated with Radiographic Damage in African-Americans with ACPA-Positive RA
Maria I. Danila¹, A. D. Steg², Xiangqin Cui³, David Redden⁴, M. R. Johnson², Richard J. Reynolds⁵, D. van der Heijde⁶, Doyt L. Conn⁷, Beth L. Jonas⁸, Leigh F. Callahan⁹, Larry W. Moreland¹⁰, P. K. Gregersen¹¹ and S. Louis Bridges Jr.¹², ¹Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, ³Biostatistics, University of Alabama at Birmingham, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁸Thurston Arthritis Research Ct, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁹Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC, ¹⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, ¹²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The clinical phenotype of rheumatoid arthritis (RA) ranges from mild joint inflammation to severe joint destruction, but molecular factors responsible for variability are incompletely…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].